Midterm postoperative prognosis of patients with severe left heart valvular disease combined with moderate or severe pulmonary hypertension treated with treprostinil.
Ning XuShu-Ting HuangKai-Peng SunZeng-Chun WangHua CaoQiang ChenPublished in: BMC cardiovascular disorders (2020)
Continuous subcutaneous infusion of treprostinil was not capable of decreasing pulmonary pressures in patients with severe left heart valvular disease combined with moderate or severe PAH during 1 year follow-up, although which some of our data suggest that might improve the symptoms and quality of life of these patients.
Keyphrases
- pulmonary hypertension
- atrial fibrillation
- pulmonary arterial hypertension
- early onset
- end stage renal disease
- heart failure
- newly diagnosed
- high intensity
- chronic kidney disease
- low dose
- aortic valve
- peritoneal dialysis
- pulmonary artery
- drug induced
- prognostic factors
- depressive symptoms
- coronary artery
- machine learning
- sleep quality
- patient reported